University Hospital Limerick

The oncology department at University Hospital Limerick is evaluating new treatment options for men with advanced disease. One study compares hormone therapy combined with darolutamide to hormone therapy alone to see if cancer progression can be delayed. Another trial tests the addition of pembrolizumab to enzalutamide to improve survival outcomes.

• ADT plus darolutamide versus ADT plus placebo
• Pembrolizumab combined with enzalutamide
• Radiographic progression‑free survival as primary endpoint
• Overall survival assessment

These investigations aim to extend the time patients remain free from disease progression and to increase overall life expectancy for those with castration‑naïve and castration‑resistant prostate cancer.

Researchers at University Hospital Limerick are conducting a trial to determine the best first‑line therapy for treatment‑naïve chronic lymphocytic leukemia. The study compares continuous ibrutinib monotherapy with fixed‑duration regimens that include venetoclax plus obinutuzumab or venetoclax plus ibrutinib.

• Ibrutinib monotherapy
• Venetoclax plus obinutuzumab fixed‑duration regimen
• Venetoclax plus ibrutinib fixed‑duration regimen
• Progression‑free survival as key outcome

The goal is to identify whether a time‑limited approach can provide comparable disease control while reducing long‑term exposure to therapy.

The oncology unit specializes in the Neoplasms therapeutic area, addressing both solid tumors and hematologic malignancies. Current research includes trials for adenocarcinoma of the prostate, metastatic castration‑resistant prostate cancer, and treatment‑naïve chronic lymphocytic leukemia.

• Three active clinical trials
• Three dedicated investigators
• Focus on improving survival and disease control
• Collaboration within a European hospital setting

By integrating innovative drug combinations and treatment strategies, the site aims to advance therapeutic options for patients across Ireland and beyond.